ACS Issues New Guidelines for PSA Cancer Screening Frequency

  • Routine Testing: Men aged 50 to 69 with average risk should discuss PSA blood tests with their physician every two years.
  • Diagnostic Nuance: An elevated PSA level does not confirm malignancy; clinical protocols now emphasize repeat testing before considering invasive biopsies.

The new guidance, published in CA: A Cancer Journal for Clinicians, represents a strategic pivot toward standardized early detection.

While previous recommendations prioritized shared decision-making without explicit screening intervals, the 2026 update provides a structured framework for primary care clinicians to follow.

For men between 70 and 74, the ACS advises individualized decision-making based on overall health and life expectancy. Routine screening is generally discouraged for men aged 75 and older, or for those with a life expectancy of less than ten years, to avoid the potential harms of over-diagnosis and aggressive treatment of slow-growing tumors.

Cancer society issues most specific prostate cancer screening guidelines yet — ABC 7 Chicago

According to data reported by El Tiempo, the ACS estimates that 333,830 new cases will be diagnosed in the United States in 2026, with approximately 36,320 deaths attributed to the disease.

“This is a true change of course,” said Philipp Dahm, a professor of urology at the University of Minnesota, as reported by The New York Times.

The updated protocol introduces a critical safety step: if a patient’s PSA level hits 3.0 ng/mL or higher (for those 45–69) or 6.5 ng/mL or higher (for those 70–74), the test must be repeated within two weeks to three months to verify the finding before further diagnostic escalation.

American Cancer Society issues new prostate cancer screening guidelines — 7News | WWNY | Watertown
Patient Profile Screening Frequency Age Range
High Risk (Family History/Black Men) Annually 45–69
Ages 70–74 Individualized 70–74
Ages 75+ Not recommended 75+

Symptoms that warrant immediate medical evaluation—regardless of screening status—include difficulty initiating urination, a weak or interrupted urinary stream, hematuria (blood in the urine), or persistent pain in the pelvic or lumbar regions.

As noted by infobae, the PSA test is a protein measurement in the blood and should never be viewed as a definitive diagnostic tool on its own.

Patients should be aware that the test carries a risk of false positives, which can lead to unnecessary anxiety or invasive procedures. The decision to screen must involve a thorough discussion with a primary care provider regarding the patient’s specific medical history and potential for over-treatment.

ACS Issues New Guidelines for PSA Cancer Screening Frequency
Photo: El Tiempo

The ACS guidelines explicitly state that for those with a life expectancy under ten years, the risks of screening—which may include complications from biopsy or surgery—frequently outweigh the benefits. Men are encouraged to discuss their personal risk factors, including genetic predispositions and baseline health, to determine the most appropriate surveillance schedule.

The updated guidance is intended to empower primary care physicians to manage the diagnostic process more effectively. “The update empowers primary care physicians to perform screenings and, subsequently, to help focus the conversation on what those tests mean if the result is abnormal,” Sanda told The Washington Post, as cited by infobae.

New prostate cancer screening guidelines increases testing — NBC News
  • American Cancer Society.
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Police Search for Missing Man Who Left Eindhoven Hospital With IV

Miguel Ángel Félix Gallardo dies at age 80 in Jalisco